Phibro Q1 net income down 41% to $3.9M; lowers FY2023 EPS guidance due to rates, tax

PHIBRO ANIMAL HEALTH CORP

2023-Q1 EPS reported $0.10 revenue$232,521,000

Q1 net sales $232.5M (+8% YoY); diluted EPS $0.10 (-41%); adjusted diluted EPS $0.21 (-18%).
Animal Health segment sales $154.9M (+10%); Mineral Nutrition $59.6M (+10%).
FY2023 guidance: net sales $960M-$1B and adjusted EBITDA $113-$118M (unchanged).
FY2023 diluted EPS guidance cut to $0.96-$1.06 from $1.11-$1.21; adjusted EPS to $1.21-$1.31 from $1.28-$1.38.
Adjusted effective tax rate guidance raised to 33% from 30% due to foreign tax credit regulations.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PHIBRO ANIMAL HEALTH CORP reported first quarter ended September 30, 2022 results: revenue $232.5 million, net income $3.9 million, EPS $0.10.

Period: first quarter ended September 30, 2022
Revenue: $232.5 million
Net income: $3.9 million
EPS: $0.10
Result: reported results

Exact text from the filing

tax rate for the year ending June 30, 2023. Highlights for the three months ended September 30, 2022 (compared to the three months ended September 30, 2021) - Net sales of $232.5 million, an increase of $17.9 million, or 8% - Net income of $3.9 million, a decrease of $2.7 million, or 41% - Diluted EPS of $0.10, a decrease of $0.07, or 41% - Adjusted EBITDA of

View on SEC.gov

Browse all earnings releases →

PHIBRO ANIMAL HEALTH CORP filing history →

Source: SEC EDGAR

accession 0001558370-22-017185

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.